293 related articles for article (PubMed ID: 17350260)
41. Searching for novel applications of the benzohomoadamantane scaffold in medicinal chemistry: Synthesis of novel 11β-HSD1 inhibitors.
Valverde E; Seira C; McBride A; Binnie M; Luque FJ; Webster SP; Bidon-Chanal A; Vázquez S
Bioorg Med Chem; 2015 Dec; 23(24):7607-17. PubMed ID: 26596711
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis, and SAR studies of novel polycyclic acids as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1).
Ye XY; Chen SY; Nayeem A; Golla R; Seethala R; Wang M; Harper T; Sleczka BG; Li YX; He B; Kirby M; Gordon DA; Robl JA
Bioorg Med Chem Lett; 2011 Nov; 21(22):6699-704. PubMed ID: 21983439
[TBL] [Abstract][Full Text] [Related]
43. The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors.
Yuan C; St Jean DJ; Liu Q; Cai L; Li A; Han N; Moniz G; Askew B; Hungate RW; Johansson L; Tedenborg L; Pyring D; Williams M; Hale C; Chen M; Cupples R; Zhang J; Jordan S; Bartberger MD; Sun Y; Emery M; Wang M; Fotsch C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6056-61. PubMed ID: 17919905
[TBL] [Abstract][Full Text] [Related]
44. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
[TBL] [Abstract][Full Text] [Related]
45. Mono-carbonyl curcumin analogues as 11β-hydroxysteroid dehydrogenase 1 inhibitors.
Lin H; Hu GX; Guo J; Ge Y; Liang G; Lian QQ; Chu Y; Yuan X; Huang P; Ge RS
Bioorg Med Chem Lett; 2013 Aug; 23(15):4362-6. PubMed ID: 23800686
[TBL] [Abstract][Full Text] [Related]
46. Phenylcyclobutyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
Zhu Y; Olson SH; Graham D; Patel G; Hermanowski-Vosatka A; Mundt S; Shah K; Springer M; Thieringer R; Wright S; Xiao J; Zokian H; Dragovic J; Balkovec JM
Bioorg Med Chem Lett; 2008 Jun; 18(11):3412-6. PubMed ID: 18440812
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and structure-activity relationship of 2-adamantylmethyl tetrazoles as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Ye XY; Yoon D; Chen SY; Nayeem A; Golla R; Seethala R; Wang M; Harper T; Sleczka BG; Apedo A; Li YX; He B; Kirby M; Gordon DA; Robl JA
Bioorg Med Chem Lett; 2014 Jan; 24(2):654-60. PubMed ID: 24360604
[TBL] [Abstract][Full Text] [Related]
48. The synthesis and SAR of novel diarylsulfone 11β-HSD1 inhibitors.
Yan X; Wang Z; Sudom A; Cardozo M; DeGraffenreid M; Di Y; Fan P; He X; Jaen JC; Labelle M; Liu J; Ma J; McMinn D; Miao S; Sun D; Tang L; Tu H; Ursu S; Walker N; Ye Q; Powers JP
Bioorg Med Chem Lett; 2010 Dec; 20(23):7071-5. PubMed ID: 20971000
[TBL] [Abstract][Full Text] [Related]
49. Use of 11alpha-deuterium labeled cortisol as a tracer for assessing reduced 11beta-HSD2 activity in vivo following glycyrrhetinic acid ingestion in a human subject.
Kasuya Y; Yokokawa A; Takashima S; Shibasaki H; Furuta T
Steroids; 2005 Feb; 70(2):117-25. PubMed ID: 15631868
[TBL] [Abstract][Full Text] [Related]
50. Pentanol derivatives from basidiomycete Catathelasma imperiale and their 11beta-hydroxysteroid dehydrogenases inhibitory activity.
Zhang L; Shen Y; Zhu HJ; Wang F; Leng Y; Liu JK
J Antibiot (Tokyo); 2009 May; 62(5):239-42. PubMed ID: 19329984
[TBL] [Abstract][Full Text] [Related]
51. Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1).
Wu SC; Yoon D; Chin J; van Kirk K; Seethala R; Golla R; He B; Harrity T; Kunselman LK; Morgan NN; Ponticiello RP; Taylor JR; Zebo R; Harper TW; Li W; Wang M; Zhang L; Sleczka BG; Nayeem A; Sheriff S; Camac DM; Morin PE; Everlof JG; Li YX; Ferraro CA; Kieltyka K; Shou W; Vath MB; Zvyaga TA; Gordon DA; Robl JA
Bioorg Med Chem Lett; 2011 Nov; 21(22):6693-8. PubMed ID: 21983444
[TBL] [Abstract][Full Text] [Related]
52. Discovery of orally active butyrolactam 11beta-HSD1 inhibitors.
Yeh VS; Kurukulasuriya R; Fung S; Monzon K; Chiou W; Wang J; Stolarik D; Imade H; Shapiro R; Knourek-Segel V; Bush E; Wilcox D; Nguyen PT; Brune M; Jacobson P; Link JT
Bioorg Med Chem Lett; 2006 Nov; 16(21):5555-60. PubMed ID: 16931002
[TBL] [Abstract][Full Text] [Related]
53. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
[TBL] [Abstract][Full Text] [Related]
54. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species.
Arampatzis S; Kadereit B; Schuster D; Balazs Z; Schweizer RA; Frey FJ; Langer T; Odermatt A
J Mol Endocrinol; 2005 Aug; 35(1):89-101. PubMed ID: 16087724
[TBL] [Abstract][Full Text] [Related]
55. Discovery of novel sulfonamides as potent and selective inhibitors against human and mouse 11β-hydroxysteroid dehydrogenase type 1.
Xia G; Liu L; Xue M; Liu H; Yu J; Li P; Chen Q; Xiong B; Liu X; Shen J
Mol Cell Endocrinol; 2012 Jul; 358(1):46-52. PubMed ID: 22410288
[TBL] [Abstract][Full Text] [Related]
56. Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.
Ye XY; Chen SY; Wu S; Yoon DS; Wang H; Hong Z; O'Connor SP; Li J; Li JJ; Kennedy LJ; Walker SJ; Nayeem A; Sheriff S; Camac DM; Ramamurthy V; Morin PE; Zebo R; Taylor JR; Morgan NN; Ponticiello RP; Harrity T; Apedo A; Golla R; Seethala R; Wang M; Harper TW; Sleczka BG; He B; Kirby M; Leahy DK; Li J; Hanson RL; Guo Z; Li YX; DiMarco JD; Scaringe R; Maxwell B; Moulin F; Barrish JC; Gordon DA; Robl JA
J Med Chem; 2017 Jun; 60(12):4932-4948. PubMed ID: 28537398
[TBL] [Abstract][Full Text] [Related]
57. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Tu H; Powers JP; Liu J; Ursu S; Sudom A; Yan X; Xu H; Meininger D; Degraffenreid M; He X; Jaen JC; Sun D; Labelle M; Yamamoto H; Shan B; Walker NP; Wang Z
Bioorg Med Chem; 2008 Oct; 16(19):8922-31. PubMed ID: 18789704
[TBL] [Abstract][Full Text] [Related]
58. Diazepane-acetamide derivatives as selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Odermatt A
Expert Opin Ther Pat; 2009 Oct; 19(10):1477-83. PubMed ID: 19780703
[TBL] [Abstract][Full Text] [Related]
59. Oxazolones as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Sutin L; Andersson S; Bergquist L; Castro VM; Danielsson E; James S; Henriksson M; Johansson L; Kaiser C; Flyrén K; Williams M
Bioorg Med Chem Lett; 2007 Sep; 17(17):4837-40. PubMed ID: 17600707
[TBL] [Abstract][Full Text] [Related]
60. Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model.
Wan ZK; Chenail E; Xiang J; Li HQ; Ipek M; Bard J; Svenson K; Mansour TS; Xu X; Tian X; Suri V; Hahm S; Xing Y; Johnson CE; Li X; Qadri A; Panza D; Perreault M; Tobin JF; Saiah E
J Med Chem; 2009 Sep; 52(17):5449-61. PubMed ID: 19673466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
